m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05099
 [1]
Non-coding RNA ZFAS1 FTO  lncRNA       miRNA   circRNA Direct Enhancement m6A modification Drp1 Drp1 FTO Demethylation : m6A sites
m6A Modification:
m6A Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
m6A Target Dynamin-1-like protein (DRP1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator ZNFX1 antisense RNA 1 (ZFAS1) LncRNA View Details
Regulated Target FTO alpha-ketoglutarate dependent dioxygenase (FTO) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary BMSC-derived exosomal KLF4 promoted lncRNA-ZFAS1 expression to repress Dynamin-1-like protein (DRP1) m6A modification by targeting FTO, thus reducing mitochondrial dysfunction and alleviating neuronal injury in ischemic stroke.
Responsed Disease Acute ischemic stroke ICD-11: 8B11
 Disease Info 
In-vitro Model
 Neuro-2a Mouse neuroblastoma Mus musculus CVCL_0470
Neuro-2a Mouse neuroblastoma Mus musculus CVCL_0470
In-vivo Model Adult C57BL/6 J mice (N = 40, 24-26 g) were used for animal experiments. Mice were randomly divided into 2 groups: sham (N = 10) and MCAO/R (N = 30). MCAO/R model mice were randomly divided into three groups: MCAO/R, MCAO/R + Exo-shNC, and MCAO/R + Exo-shKLF4, and mice were injected with Exo-shNC and Exo-shKLF4 through the tail vein (the injection concentration was 100 μg exosomes in 100 L PBS according to the previous study).
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
8B11: Acute ischemic stroke 7 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name PEG-bHb-CO Phase 2 [2]
Synonyms
Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0A6LT
 Compound Name DM199 Phase 2 [3]
External Link
TTD: DS70MP
 Compound Name BIIB131 Phase 2 [4]
Synonyms
(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007
    Click to Show/Hide
External Link
CID: 50898407
TTD: DEV2G0
 Compound Name BMS-986177 Phase 2 [5]
Synonyms
Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2
    Click to Show/Hide
External Link
CID: 118277544
TTD: DB6XD8
 Compound Name SonoLysis Prolyse Phase 2 [6]
External Link
TTD: D08JGE
 Compound Name ACT017 Phase 1/2 [7]
External Link
TTD: DPG5T9
 Compound Name Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 Patented [8]
Synonyms
PMID27998201-Compound-16
    Click to Show/Hide
External Link
CID: 1720818
TTD: D0UX4J
References
Ref 1 Bone Marrow Mesenchymal Stem Cell-Derived Exosomal KLF4 Alleviated Ischemic Stroke Through Inhibiting N6-Methyladenosine Modification Level of Drp1 by Targeting lncRNA-ZFAS1. Mol Neurobiol. 2023 Jul;60(7):3945-3962. doi: 10.1007/s12035-023-03301-2. Epub 2023 Mar 31.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 ClinicalTrials.gov (NCT04123613) Multiple Doses of DM199 in Patients With Chronic Kidney Disease. U.S. National Institutes of Health.
Ref 4 ClinicalTrials.gov (NCT05764122) A Multicenter, Operationally Seamless, Double-Blind, Dose-Ranging, Placebo-Controlled, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Intravenous BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well. U.S.National Institutes of Health.
Ref 5 ClinicalTrials.gov (NCT03766581) A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel (AXIOMATIC-SSP). U.S. National Institutes of Health.
Ref 6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004567)
Ref 7 ClinicalTrials.gov (NCT03803007) Acute Ischemic Stroke Interventional Study (ACTIMIS). U.S. National Institutes of Health.
Ref 8 Cathepsin B and L inhibitors: a patent review (2010 - present). Expert Opin Ther Pat. 2017 Jun;27(6):643-656. doi: 10.1080/13543776.2017.1272572. Epub 2016 Dec 23.